STOCK TITAN
  1. Home
  2. News
  3. VNRX

VolitionRX Ltd - VNRX STOCK NEWS

Welcome to our dedicated news page for VolitionRX (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on VolitionRX.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VolitionRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VolitionRX's position in the market.

News
Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
Rhea-AI Summary
VolitionRx launches Nu.Q® Vet Cancer Test in-clinic in U.S. and Europe through Antech, providing rapid, accurate, and cost-effective cancer screening for high-risk breeds and older dogs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.67%
Tags
none
-
News
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
Rhea-AI Summary
VolitionRx (VNRX) reports a successful fiscal year 2023 with significant financial growth and strategic partnerships. The company's Nu.Q® Vet Cancer Test gained traction in the companion animal healthcare sector, resulting in substantial sales and collaborations. Volition also made progress in its Nu.Q® NETs pillar and introduced a groundbreaking cancer detection method, Capture-PCR™. Financially, the company saw a notable increase in revenue, received substantial milestone payments, and maintained a healthy cash position. Volition's management remains optimistic about future milestones and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
earnings
-
News
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
Rhea-AI Summary
VolitionRx (VNRX) to host conference call to discuss Q4 and full year 2023 financial results and business update on March 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.75%
Tags
earnings
News
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) partners with Fujifilm Vet Systems to supply Nu.Q® Vet Cancer Test in Japan, enhancing early cancer detection for dogs. The accessible test aims to improve patient care through early intervention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
none
-
News
Volition appoints Dr Andrew Retter as Chief Medical Officer
Rhea-AI Summary
VolitionRx appoints Dr. Andrew Retter as Chief Medical Officer to lead medical efforts aligned with patient needs. Dr. Retter brings expertise in Intensive Care Medicine and Haematology, enhancing Volition's focus on cutting-edge diagnostic solutions for early disease detection and treatment monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
management
-
News
Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
Rhea-AI Summary
VolitionRx Limited (NYSE American: VNRX) is participating in a webinar hosted by Edison Group to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test. The webinar will include updates from Volition's Chief Commercial Officer and a leading UK-based Intensive Care Consultant. The event aims to provide an understanding of sepsis, highlight the challenges in diagnosing, treating, and monitoring the disease, and outline Volition's next steps towards commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
News
Volition Issues Business Review 2023
Rhea-AI Summary
VolitionRx Limited (VNRX) Issues Business Review of 2023, Highlighting Key Achievements
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.1%
Tags
none
-
News
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre
Rhea-AI Summary
VolitionRx Limited (VNRX) secures Euro 5.0 million financing from Wallonie Entreprendre S.A. for the ongoing development of its Nu.Q® product portfolio, including clinical and regulatory programs for Nu.Q® NETs, aiming to aid in the early diagnosis of diseases such as sepsis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
News
Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society
Rhea-AI Summary
VolitionRx Limited (NYSE AMERICAN: VNRX) is presenting at the 5th Annual Congress of Liquid Biopsy in Madrid, Spain. The company's Chief Scientific Officer, Dr. Jake Micallef, will present a session on 'An Introduction to circulating nucleoproteins.' Volition recently unveiled a new cancer detection method generating significant interest from diagnostic and liquid biopsy companies. The method involves the physical isolation of tumor-derived ctDNA fragments from blood, allowing for the detection of a range of liquid and other cancers, including at early stages, with high specificity using a simple, low-cost PCR test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
News
VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
VolitionRx Limited (VNRX) Announces Strong Financial Results in Q3 2023 and Business Update. The company reported a significant revenue growth of 185% year-over-year and made notable progress with its Nu.Q® NETs pillar, securing FDA agreement and presenting new data at ESICM congress. The company's innovative cancer detection method unveiled at ESMO 2023 received positive feedback, and they are expanding their Nu.Q® Vet Cancer Test globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
earnings
Stock VNRX logo
VolitionRX Ltd

NYSE:VNRX

VNRX Rankings

#4483 Ranked by Market Cap
#4895 Ranked by Stock Gains
N/A Ranked by Dividends

VNRX Stock Data

56.22M
62.70M
23.92%
7.97%
0.6%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Henderson

About VNRX

volitionrx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats. volitionrx’s development activities are currently centered in belgium with a focus on bringing its revolutionary diagnostic products to market first in europe, then the u.s. and worldwide. you can find more information about volitionrx at our website at www.volitionrx.com, on twitter at www.twitter.com/volitionrx, linkedin at http://www.linkedin.com/company/volitionrx or facebook at www.facebook.com/volitionrx.